



## **Board Appointment – Dr Pamela Kirby**

**London, 6 November 2014** - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) (OTC: HKMPY) ("**Hikma**"), the FTSE 250 pharmaceuticals company, is today announcing the appointment of Dr Pamela Kirby as an independent non-executive director of the Company with effect from 1 December 2014. Dr Kirby will join the Audit, Remuneration and Compliance, Responsibility and Ethics (CRE) Committees.

**Said Darwazah, Chairman and Chief Executive**, said: "I am delighted that Dr Kirby has agreed to join our Board. She brings a wealth of pharmaceutical, international, strategic, and listed company experience. She has a strong track record from her senior executive and board-level roles, and complements our culture and style perfectly. I am confident that she will enhance the capabilities of the Board, and that we are now in an even stronger position to lead our company going forward."

### **Dr Pamela Kirby**

Dr Pamela Kirby was CEO of Quintiles Transnational Corp and has held senior executive positions in F Hoffmann-La Roche Ltd and AstraZeneca plc. Dr Kirby has chaired Oxford Immunotec Ltd and was senior independent director of Informa plc. Dr Kirby has previously held non-executive director positions with Smith & Nephew plc, Novo Nordisk A/S, Curalogic A/S and Oscient Pharmaceuticals Corp.

Dr Kirby is chairman of Scynexis Inc and a non-executive director of DCC plc and Victrex plc.

Dr Kirby holds a first-class Bachelor of Science degree in Pharmacology and a PhD in Clinical Pharmacology from the University of London.

**-- ENDS --**

### **Enquiries:**

#### **Hikma Pharmaceuticals PLC**

Peter Speirs, Company Secretary +44 (0)20 7399 2772

Susan Ringdal, Vice President for Investor Relations +44 (0)20 7399 2760

#### **Financial Dynamics**

Matthew Cole & Ben Atwell +44 (0)20 3727 1000

### **Notes to Editors:**

#### **About Hikma**

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2013,

Hikma achieved revenues of \$1,365 million and profit attributable to shareholders of \$212 million.